A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma

Update Il y a 4 ans
Reference: NCT02079519

Woman and Man

  • | Country :
  • Austria
  • | organs :
  • -
  • | Specialty :
  • -

Extract

This study evaluated the efficacy and safety of Avastin (bevacizumab, 5 mg/kg intravenously every 2 weeks) in patients with multiple myeloma, relapsed/refractory after at least 2 lines of prior therapy.


Inclusion criteria

  • Multiple myeloma

Links